How Drug Price Negotiation Is Reshaping Clinical Trial Pipelines
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
How Drug Price Negotiation Is Reshaping Clinical Trial Pipelines
-
Narrated by:
-
Written by:
About this listen
Health Affairs' Rob Lott interviews So-Yeon Kang of Georgetown University about her recent paper exploring trends in biopharmaceutical clinical trials after The Inflation Reduction Act of 2022 authorized Medicare to negotiate prices for selected drugs.
Order the January 2026 issue of Health Affairs.
Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcast
No reviews yet